In a clinical trial at the Massachusetts General Hospital (MGH) Cancer Center, Thomas J. Lynch uses an experimental drug as well as tyrosine kinase inhibitors, such as Iressa and Tarceva, to treat patients suffering from non-small-cell lung cancer who have mutations within the epidermal growth factor receptor gene (EFGR).